CNBC Fast Money

2026-06-29 · Hosted by Melissa Lee · CNBC

Executive Summary

Frank Holland hosts as the NASDAQ rides a five-day losing streak into the weekend (~5% on the week), its longest stretch since January, with BofA’s Michael Hartnett flagging a $9 billion+ tech outflow — the first since March and a sharp reversal from the prior week’s $19B inflow. The desk debates whether the broadening trade is real (equal-weight S&P doubling cap-weight over two months; industrials +5%, financials +4.5%) and whether the AI slump is buyable. Gene Munster argues a NASDAQ pullback is imminent but the AI story is “second inning,” with the law of large numbers the biggest risk. SpaceX fell back to its $150 IPO price (-16% on the week), oil dropped below $70 amid live U.S.-Iran strikes, biotech’s XBI ripped +10% on the week, and traders eyed Nike earnings with an implied ~8.5% move.

Key Stories & Changes

1. The Tech Slump & Broadening Debate

  • NASDAQ down five straight days, ~5% on the week; longest losing streak since January

  • BofA’s Hartnett: >$9B tech outflow, first since March; prior week saw >$19B inflow

  • Mag 7 down >5% on the week, slumping ~12% on the month

  • Equal-weight S&P doubling cap-weight over two months; industrials +5%, financials +4.5%

  • Rates fell double digits since Worsh became chair; lower oil offsets floating-rate-debt risk (32% of Russell, 6% of S&P)

2. Gene Munster on the Mag 7 & Nvidia

  • Calls the slump “much to do about nothing”; cites 10 ~10% pullbacks 1995–2000 vs. only ~4 in the AI era

  • Expects a NASDAQ pullback within ~5 weeks (before June earnings) but sees AI in the “second inning”

  • Law of large numbers is the biggest market risk: Mag 7 revenue +3% over three months while stocks fell ~7%

  • Micron grew 370% in May quarter, ~340% guided for August, but only ~60% expected next year

  • Nvidia ~90% growth this year stepping down to ~40–60% next; Deepwater sold Nvidia months ago on law of large numbers

  • Courtney Garcia cites Goldman estimate: AI capex ~$765B now → ~$1.6T by 2031

3. SpaceX Falls Back to IPO Price

  • SPACEX: SpaceX — -16% (week) — Back to $150 IPO open; added to Russell, NASDAQ-100 entry ~July 6

  • ~30% of company headed to passive hands, forcing index buying; Grasso nibbling, sees a floor

  • Tim Seymour: “nothing has a floor”; sum-of-parts suggests overvalued above a discount it should trade at

4. Oil Below $70 Amid Live Strikes

  • WTI closed below $70, down >25% on the month (~48% off intraday highs)

  • U.S. CENTCOM struck Iran after the Ever Lovely attack; IRGC vowed a “swift and decisive” counter-response

  • Desk consensus: market already priced past the conflict; backwardation signals lower forward prices; good for foreign equities

5. Biotech & Pharma Rip

  • XBI +10% on the week, +~83% YoY; Dyne (Dernock) +13% (up 128% YTD), ABSI +$100M Lily investment

  • Lily hit a new all-time high; J&J, Bristol, even Pfizer higher

  • $275B+ revenue at risk from patent cliffs → continued “white-hot M&A”; Mike Co prefers diversified XLV and United Health at a discount

6. Old-Economy & Single Names

  • Luke Sarsfield (Ridgepost Capital): private-market opportunity in old-economy logistics/industrial firms; AI as low-hanging efficiency fruit; “it never left”

  • ISM in expansion for five straight months; Caterpillar now treated as an AI play

  • GameStop reaffirmed pursuit of ~$55B eBay acquisition; guided adjusted EBITDA >$600M (vs. $345M)

  • Nike down 36% YTD (lowest since 2014); options imply ~8.5% move on Tuesday earnings; China weakness, no marquee athlete

1. The Broadening Trade Gets Real

With lower yields, lower oil and lower commodities, the equal-weight S&P is outpacing the cap-weight index and old-economy sectors (industrials, financials, homebuilders, staples) are responding. The desk broadly believes the rotation can continue — not as the end of AI, but as capital seeks shorter-duration, cheaper value while AI’s payoff timeline remains distant.

2. The Law of Large Numbers as the AI Ceiling

Munster’s central thesis: even spectacular AI growth (Micron +370%, Nvidia +90%) decelerates sharply, and investors struggle to underwrite ever-bigger absolute numbers. Multiple compression amid rising revenue is the tell — the biggest near-term risk isn’t fundamentals but appetite for the math.

3. Picks-and-Shovels Over Pure AI

Courtney Garcia and others reframe the trade toward AI infrastructure and energy “picks and shovels” plus old-economy companies that will benefit from AI productivity rather than the over-owned direct AI names — a barbell favoring under-performed industrials.

4. Oil’s Geopolitical Premium Evaporates

Despite live U.S.-Iran strikes and IRGC counter-threats, oil sits below pre-war levels in an oversupplied state (Saudis pumping, Iraq wanting to leave OPEC). The market has structurally moved past the conflict, a tailwind for foreign equities and rate-sensitive sectors.

5. Biotech’s M&A-Driven Renaissance

Patent cliffs ($275B+ revenue at risk) are forcing relentless M&A, powering XBI’s +83% year. The debate is small-cap acquisition targets (Grasso) vs. diversified, reasonably-valued large-cap healthcare (Mike Co’s XLV/UNH). —-

Sentiment Analysis

Overall Market Sentiment: Rotational / Constructively Cautious

The desk sees a real tech slump and an imminent pullback but treats it as opportunity and rotation rather than the end of the bull market.

Risk Factors Highlighted

Law of large numbers: Decelerating mega-cap growth and multiple compression are the biggest market risk.

Tech outflows: $9B+ exodus signals fragile conviction after a $19B inflow week.

Hyperscaler free-cash-flow depletion: Companies raising money instead of self-funding raises sustainability questions.

Imminent NASDAQ pullback: Munster expects a ~10% pullback within five weeks.

SpaceX valuation/lockups: Overvalued on sum-of-parts; VC lockup expirations could add supply.

Iran counter-strike risk: IRGC promises a “swift and decisive” response to U.S. strikes.

AI capex scale: ~$1.6T projected by 2031 — Ben Snyder reportedly thinks they’re overspending.

Patent cliffs: $275B+ pharma revenue at risk requires constant M&A to replace.

Nike China weakness: Falling sales and lost marquee endorsements; turnaround timing unclear.

Crypto instability: Ethereum repeatedly breaks support; holders appear absent.

This episode was covered in today’s The Market Signal — 2026-06-29, a cross-source synthesis of multiple podcast reports.

Keep Reading